Biotech Busine$$ Daily (ACOR, CERS, DNDN, STEM, TCM)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Biotechs always have some news movers regardless of which direction the markets are headed.  Here are some of the top movers in biotech today, although we would note that many of the largest market cap biotech stocks are up on a day that the DJIA, S&P 500, and NASDAQ are dragging lower.

Acorda Therapeutics (NASDAQ: ACOR) down 5% today to $19.56. Yesterday, a study the company sponsored on multiple sclerosis was released showing the negative impact MS had on people suffering from the disease. The 52 week range is $15.80 to $28.14.

Cerus Corp. (NASDAQ: CERS) stock up over 6% today to $543 on an announcement that the 32 studies of their INTERCEPT Blood System, a system that assists patients that underwent blood transfusions and avian flu deactivation, will be presented at the International Congress of the International Society of Blood Transfusion. The 52-week range is $4.18 to $10.29

Dendreon (NASDAQ: DNDN) up almost 8% in mid-day trading on no new news. Stocks are trading $0.40 higher at $5.16. The stock seems to be recovering from a slide March 12 when the company changed its tactics on for Phase III testing on prostate cancer immunotherapy Provenge.

StemCells Inc. (STEM) up by almost 8% today to $1.49, possibly in response to Nancy Reagan’s endorsement of Republican presidential nominee, John McCain, both supporters of stem cell research. The 52-week range is $1.00 to $3.09.

Tongjitang Chinese Medicines Co. (NASDAQ: TCM) up today on news that the company has appointed Morgan Stanley Asia Limited as its financial advisor. Shares have edged up $0.45 or by 5%, to $8.51 in mid-day trading on relatively high trading volume. The 52 week high is $12.88.

Rachel Lopez
March 26, 2008

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618